Centre Francois Baclesse
baclesse.frTotal trials
117
Active
32
Phase 3
9
Total enrollment
14,517
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 8 of 8 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| cabozantinib and nivolumab | — | — | — | — | — | 1 | |
| Systematic RAI-treatment | — | — | — | — | — | 1 | |
| Talazoparib + Avelumab | — | — | — | — | — | 1 | |
| tests to determine HRD status | — | — | — | — | — | 1 | |
| 5Fluorouracile and Mitomycin-C | — | — | — | — | — | 1 | |
| Olaparib | — | — | — | — | — | 1 | |
| Temozolomide | — | — | — | — | — | 1 | |
| Mutation Burden cfMB analysis | — | — | — | — | — | 1 |
Next readouts
- 2021-06-25
- 2023-07-28
- 2026-09-13
- 2027-07-15
- 2028-10
- 2031-02
- 2031-06
Top conditions
- Breast Cancer20
- Cancer15
- Head and Neck Cancer6
- Ovarian Cancer4
- Oncology3
- Radiation Toxicity3
- Radiotherapy3
- Surgery2
Frequently asked questions about Centre Francois Baclesse
- How many clinical trials does Centre Francois Baclesse have on ClinicalTrials.gov?
- Centre Francois Baclesse is listed as the lead sponsor on 117 clinical trials in ClinicalTrials.gov, 32 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Centre Francois Baclesse's trials are in Phase 3?
- 9 of Centre Francois Baclesse's trials are in Phase 3, spread across 8 active drug programs.
- What therapeutic areas does Centre Francois Baclesse focus on?
- Centre Francois Baclesse's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Cancer, Head and Neck Cancer, Ovarian Cancer, Oncology.
- When are Centre Francois Baclesse's next clinical trial readouts?
- Centre Francois Baclesse has 7 upcoming primary-completion readouts tracked here; the soonest is “Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life”, expected around 2021-06-25.